Drugs.com
NOVEMBER 5, 2024
TUESDAY, Nov. 5, 2024 -- The omega-3 and omega-6 fatty acids in fish oil supplements might help protect people from cancer, a new study claims.Study participants with higher levels of omega-3s had lower rates of colon, stomach, lung and other.
BioPharma Drive: Drug Pricing
NOVEMBER 5, 2024
The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other tests, although Wall Street analysts were divided on how the two drugs compare.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Science Daily: Pharmacology News
NOVEMBER 5, 2024
Large language models can achieve incredible performance on some tasks without having internalized a coherent model of the world or the rules that govern it, researchers find. This means these models are likely to fail unexpectedly if they are deployed in situations where the environment or task slightly changes.
Drugs.com
NOVEMBER 5, 2024
TUESDAY, Nov. 5, 2024 -- Current treatments sometimes fail to help people with “wet” age-related macular degeneration -- and researchers now think they know why.Wet AMD is caused by an overgrowth of blood vessels in the retina, the light-sensing tis.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
BioPharma Drive: Drug Pricing
NOVEMBER 5, 2024
The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.
Drugs.com
NOVEMBER 5, 2024
TUESDAY, Nov. 5, 2024 -- People with diabetes face a number of health challenges related to their chronic condition, and loss of vision due to retinal damage is one of them.“Diabetes can silently damage a person’s most precious sense, their sight, b.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drugs.com
NOVEMBER 5, 2024
TUESDAY, Nov. 5, 2024 -- Exposure to any one of 22 pesticides may bring heightened odds of developing prostate cancer, a new analysis suggests.The study was conducted over decades because prostate cancer is known to grow very slowly, noted a team.
Science Daily: Pharmacology News
NOVEMBER 5, 2024
Romance is a complex affair in humans. There's personality, appearance, seduction, all manner of physical and social cues. Mosquitoes are much more blunt. Mating occurs for a few seconds in midair. And all it takes to woo a male is the sound of a female's wingbeats. Imagine researchers' surprise when a single change completely killed the mosquitoes' libidos.
Drug Patent Watch
NOVEMBER 5, 2024
The development and approval of biosimilars have become increasingly important in the biopharmaceutical industry, offering cost-effective alternatives to original biological medicines. However, biosimilars pose unique challenges in terms of risk management due to their complex nature and potential for immunogenicity.
Science Daily: Pharmacology News
NOVEMBER 5, 2024
Hydrogen, a promising fuel, has extensive applications in many sectors. However, its safe and widespread use necessitates reliable sensing methods. While tunable diode laser absorption spectroscopy (TDLAS) has proved to be an effective gas sensing method, detecting hydrogen using TDLAS is difficult due to its weak light absorption property in the infrared region.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
addgene Blog
NOVEMBER 5, 2024
Pre-made viruses have become increasingly accessible and are useful for saving time and avoiding potentially costly set-ups. However, there are many cases where the specific viral particles you need are not available, or the cost of custom viruses are too high for your budget. In those cases, you’ll need to produce your viruses in-house.
BioPharma Drive: Drug Pricing
NOVEMBER 5, 2024
The company, which is only three years removed from one of biotech’s most lucrative IPOs, will cut jobs for a third time and invest more heavily in cell therapies for diabetes and lupus.
Drugs.com
NOVEMBER 5, 2024
TUESDAY, Nov. 5, 2024 -- Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 a.
Science Daily: Pharmacology News
NOVEMBER 5, 2024
At the end of the last global ice age, the deep-frozen Earth reached a built-in limit of climate change and thawed into a slushy planet. Results provide the first direct geochemical evidence of the slushy planet -- otherwise known as the 'plume-world ocean' era -- when sky-high carbon dioxide levels forced the frozen Earth into a massive, rapid melting period.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Covalent Modifiers
NOVEMBER 5, 2024
Lavleen Mader, Jessica Borean and Jeffrey W Keillor RSC Med. Chem. 2024 DOI 10.1039/D4MD00707G Irreversible targeted covalent inhibitors, in the past regarded as inappropriately reactive and toxic, have seen a recent resurgence in clinical interest. This paradigm shift is attributed to the exploitation of the two-step mechanism, in which a high affinity and selectivity (i.e., low KI) scaffold binds the target and only then does a pendant low intrinsic reactivity warhead react with the target (mo
Perficient: Drug Development
NOVEMBER 5, 2024
Hello Trailblazers! Salesforce provides users with a robust reporting toolset that enables businesses to analyze their data, identify trends, and drive smarter decision-making. Among the various types of reports available in Salesforce, Summary Reports stand out as one of the most popular due to their ability to group and summarize data effectively.
Alta Sciences
NOVEMBER 5, 2024
Liquid-Filled Capsules: An Attractive, Marketable Solution rmieras Tue, 11/05/2024 - 14:03 A Scalable Solution for Solubility Challenges Poorly soluble molecules comprise more than 70% to as much as 90%, as of 2024, 1 of the small molecule products entering the drug development pipeline today, thanks to updated screening methods and bioavailability enhancements.
Perficient: Drug Development
NOVEMBER 5, 2024
Welcome to my recap of Sitecore Symposium 2024! The week continued with numerous insightful sessions, informative workshops, and exciting new announcements. Here are my session notes and takeaways from the final day at Symposium, day three. Opening Keynote Opening keynote with Brendan Hunt The morning kicked off on a high note with a special guest appearance by Brendan Hunt, who plays Coach Beard on Ted Lasso.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Fierce BioTech
NOVEMBER 5, 2024
Single Cell RNA Profiling FFPE Tissue Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Quality control metrics highlight the optimal conditions for processing FFPE curls, with the highest DV200 samples yielding the most robust data. Download this whitepaper to learn more. jbuckley Tue, 11/05/2024 - 17:10 Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consist
Perficient: Drug Development
NOVEMBER 5, 2024
Ever wondered what a day looks like when technology meets teamwork? As a technical architect at Perficient, Rodrigo Vargas builds solutions and bridges between teams, tools, and ideas. From streamlining automation across multiple frameworks to shaping roadmaps and client strategies, every day is a blend of technical challenges and creative collaboration.
Drugs.com
NOVEMBER 5, 2024
TUESDAY, Nov. 5, 2024 -- An elevated heart rate could provide an important clue to which Black adults often have a dangerous heart rhythm disorder, a new study finds.Higher resting heart rate is associated with increased risk of atrial.
Perficient: Drug Development
NOVEMBER 5, 2024
Having spent nearly six years at Perficient, Martin Krahl serves as Director of Software Engineering, where he balances strategy, mentorship, and technical excellence. From identifying business opportunities to building high-performing teams, his work ensures smooth project delivery and lasting impact. Curious to learn more about his journey, accomplishments, and advice?
Drugs.com
NOVEMBER 5, 2024
TUESDAY, Nov. 5, 2024 -- Banning menthol cigarettes could help convince smokers quit the habit, a new study finds.People who prefer menthol cigarettes would rather buy nicotine gum or other nicotine replacement therapies than switch to traditional.
Conversations in Drug Development Trends
NOVEMBER 5, 2024
In preparation for World Orphan Drug Congress Europe, we interviewed Nathan Chadwick, Senior Director, Therapeutic Strategy Lead, Rare Disease, and Derek Ansel, MS, LCGC, Vice President, Therapeutic Strategy Lead, Rare Disease, to hear their insights into the current progress in rare disease research and their hopes for 2025. What was the biggest development in rare disease in 2024, and how has that impacted clinical research or patient outcomes?
Drugs.com
NOVEMBER 5, 2024
TUESDAY, Nov. 5, 2024 -- Canadian researchers have found that about 1 in every 3 people newly diagnosed with cancer experienced at least one emergency department visit sometime during the three months prior to their diagnosis.Many of the visits.
Perficient: Drug Development
NOVEMBER 5, 2024
Revolutionizing Business Operations with AI Agents We are thrilled to announce that Perficient has been added to the Agentforce Partner Network , a groundbreaking ecosystem introduced by Salesforce. This network is designed to revolutionize how businesses leverage AI agents to enhance customer success and operational efficiency. The Agentforce Partner Network brings together leading partners to build and deploy third-party AI agents and agent actions.
Drugs.com
NOVEMBER 5, 2024
TUESDAY, Nov. 5, 2024 -- In an early sign that the mpox outbreak in Africa might be ebbing, some health officials report that case counts seem to be stabilizing in the Congo, the epicenter of the outbreak.The World Health Organization first.
ProRelix Research
NOVEMBER 5, 2024
Clinical trials are necessary in advancing medical research and health care options by allowing new treatments to be introduced in the market through safety and efficacy testing in humans. Successful […] The post Clinical Trials and Human Subject Protection as per US FDA appeared first on ProRelix Research.
BioPharma Drive: Drug Pricing
NOVEMBER 5, 2024
Rallybio is headed into a mid-stage trial with enough cash to last it through 2026, but biotech's down market has made the company's journey difficult.
Expert insights. Personalized for you.
115 
Let's personalize your content